CIK 0001579428 · Large accelerated filer
Axsome Therapeutics, Inc.
Sign in to watch- Ticker
- AXSM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 454241907
- Phone
- (212) 332-3241
- Business address
- ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,086,500
- in 1 filing, $2.1M under 10b5-1 plans
Net −$2,086,500. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-06 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −29,450 | $172.33 | $5.1M | 7,229 |
| 2026-01-06 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −29,450 | 63,671 | ||
| 2026-01-05 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +78,703 | $8.02 | $631K | 85,932 |
| 2026-01-05 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −78,703 | $171.28 | $13.5M | 7,229 |
| 2026-01-05 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −78,703 | 93,121 | ||
| 2025-12-31 | Saad Mark E Director | Option exercise 10b5-1 | +6,231 | $8.02 | $50K | 16,233 |
| 2025-12-31 | Saad Mark E Director | Sale 10b5-1 | −6,231 | $165.18 | $1.0M | 10,002 |
| 2025-12-31 | Saad Mark E Director | Option exercise 10b5-1 | +31,346 | $4.95 | $155K | 41,348 |
| 2025-12-31 | Saad Mark E Director | Sale 10b5-1 | −31,346 | $165.18 | $5.2M | 10,002 |
| 2025-12-31 | Saad Mark E Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,231 | 0 | ||
| 2025-12-31 | Saad Mark E Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −31,346 | 0 | ||
| 2025-12-04 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +10,558 | $8.02 | $85K | 17,787 |
| 2025-12-04 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −10,558 | $148.18 | $1.6M | 7,229 |
| 2025-12-04 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,558 | 171,824 | ||
| 2025-12-03 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +20,163 | $8.02 | $162K | 27,392 |
| 2025-12-03 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −20,163 | $146.94 | $3.0M | 7,229 |
| 2025-12-03 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,163 | 182,382 | ||
| 2025-12-02 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +49,252 | $8.02 | $395K | 56,481 |
| 2025-12-02 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −49,252 | $144.59 | $7.1M | 7,229 |
| 2025-12-02 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −49,252 | 202,545 |
Page 5 of 22 · 422 trades